ImmunoGen announced positive results from its Phase 2 study of trastuzumab emtansine (T-DM1) for the treatment of HER2-positive metastatic breast cancer (MBC). This randomized, 137-patient trial showed that patients treated with T-DM1 had a significant improvement in progression-free survival compared with patients treated with Herceptin (trastuzumab) plus chemotherapy (docetaxel). T-DM1 is in Phase 3 testing for second-line and first-line treatment of HER2-postive MBC.
Trastuzumab emtansine utilizes ImmunoGen’s Targeted Antibody Payload (TAP) technology with the trastuzumab antibody developed by Genentech.
For more information call (781) 895-0600 or visit www.immunogen.com